USANA Health Sciences reported a decrease in net sales and net earnings for the fourth quarter of 2024 compared to the same period in 2023. Diluted EPS also saw a significant decline. The company completed the acquisition of a controlling stake in Hiya Health Products, which contributed approximately $2 million to net sales in Q4 2024.
Net sales for Q4 2024 were $214 million, down from $221 million in Q4 2023.
Net earnings for Q4 2024 were $4.5 million, a substantial decrease from $16.8 million in Q4 2023.
Diluted EPS for Q4 2024 was $0.23, compared to $0.87 in Q4 2023.
Adjusted diluted EPS for Q4 2024 was $0.64, down from $0.87 in Q4 2023, and Adjusted EBITDA was $25 million, down from $32 million.
USANA provided its fiscal year 2025 outlook, expecting consolidated net sales between $920 million and $1.0 billion, and diluted EPS between $1.50 and $2.20. The outlook includes the impact of the Hiya acquisition and certain transaction-related expenses.
Analyze how earnings announcements historically affect stock price performance